Answers are grounded in this paper and cite their sources.
Background: Obesity is a disease associated with high direct medical costs and high indirect costs resulting from productivity loss. The high prevalence of obesity generates the need for payers to identify cost-effective weight loss approaches. Among various weight management techniques, the OPTI (Optifast ® ) program is a clinically recognised total meal replacement diet that can lead to significant weight loss and reduction in complications. This study’s objective is to assess OPTI program’s cost-effectiveness in Switzerland in comparison to “no intervention” and pharmacotherapy. Methods: An event-driven decision-analytic model was used to estimate the payer’s cost savings through the reimbursement of OPTI program over a 1-year period as well as a lifetime in Switzerland. The analysis was performed on a broad population of people with obesity with a body mass index (BMI) higher than 30 kg/m 2 following the OPTI program vs two comparators (liraglutide and “no intervention”). The model incorporated a higher risk of complications due to an increased BMI and their related healthcare costs. Data sources included published literature, clinical trials, official Swiss price/tariff lists and national population statistics. The primary perspective was that of a Swiss payer. Scenario analyses – for example, for patients with existing complications (such as myocardial infarction, stroke, type 2 diabetes mellitus) or severe obesity – were conducted to test the robustness of the results. Results: The OPTI program results in cost savings of CHF 20,886 (€ 18,724) and CHF 15,382 (€ 13,790) per person compared with “no intervention” and liraglutide 3 mg, respectively. In addition, OPTI program led to 1.133 and 0.734 quality-adjusted life years (QALYs) gained respectively against its comparators. Scenario analyses showed similar outcomes with cost savings and QALYs gained. Conclusion: OPTI program is a dominant strategy compared to “no intervention” and liraglutide 3 mg as it leads to both cost savings and QALY gain. Therefore, reimbursing the OPTI program for patients with obesity would be cost-effective for Swiss payers.
No takes yet. Share an insight, caveat, or question.
Nuijten et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: